These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 7940371

  • 1. [The effect of recombinant human erythropoietin during hemodialysis on the thrombocyte and erythrocyte functions of patients with chronic kidney failure].
    Rud'ko IA, Balashova TS, Kubatiev AA, Ermolenko VM.
    Ter Arkh; 1994; 66(6):57-60. PubMed ID: 7940371
    [Abstract] [Full Text] [Related]

  • 2. [The effect of recombinant human erythropoietin on thrombocyte aggregation capacity and on the blood prostanoid level in patients with chronic kidney failure on hemodialysis].
    Rud'ko IA, Pokrovskiĭ IuA, Ermolenko VM, Kubatiev AA.
    Ter Arkh; 1991; 63(10):128-30. PubMed ID: 1805410
    [Abstract] [Full Text] [Related]

  • 3. [The efficacy of an erythropoietin-calcitriol combination in patients with chronic kidney failure on programmed hemodialysis].
    Nikolaev AIu, Klepikov PV, Lashutin SV, Kukhtevich AV.
    Ter Arkh; 1995; 67(5):27-31. PubMed ID: 7638771
    [Abstract] [Full Text] [Related]

  • 4. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
    Janicka L, Majdan M, Dmoszyńska A, Ksiazek A, Berger B, Baranowska E.
    Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
    [Abstract] [Full Text] [Related]

  • 5. Red blood cell membrane lipid peroxidation and resistance to erythropoietin therapy in hemodialysis patients.
    Gallucci MT, Lubrano R, Meloni C, Morosetti M, Manca di Villahermosa S, Scoppi P, Palombo G, Castello MA, Casciani CU.
    Clin Nephrol; 1999 Oct; 52(4):239-45. PubMed ID: 10543326
    [Abstract] [Full Text] [Related]

  • 6. Effect of erythropoietin therapy and selenium supplementation on selected antioxidant parameters in blood of uremic patients on long-term hemodialysis.
    Adamowicz A, Trafikowska U, Trafikowska A, Zachara B, Manitius J.
    Med Sci Monit; 2002 Mar; 8(3):CR202-5. PubMed ID: 11887037
    [Abstract] [Full Text] [Related]

  • 7. [Blood viscosity and the erythrocyte charge in patients with chronic kidney failure and suppurative intoxication and during the correction of these conditions by hemosorption and hemodialysis].
    Samoĭlov MV, Zakharchenko VN, Larionov SM, Naumov AG, Danilkov AP, Zakharova VD, Ivleva AI, Kudriavtsev IuV, Surikova TP.
    Urol Nefrol (Mosk); 1993 Mar; (4):34-7. PubMed ID: 8310565
    [Abstract] [Full Text] [Related]

  • 8. [Effect of recombinant human erythropoietin on hemodynamics in chronic hemodialysis patients].
    Tomura S.
    Nihon Rinsho; 1991 Dec; 49 Suppl():695-701. PubMed ID: 1808338
    [No Abstract] [Full Text] [Related]

  • 9. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis.
    Sirolli V, Strizzi L, Di Stante S, Robuffo I, Procopio A, Bonomini M.
    Thromb Haemost; 2001 Sep; 86(3):834-9. PubMed ID: 11583316
    [Abstract] [Full Text] [Related]

  • 10. [The effect of human recombinant erythropoietin on the lipid peroxidation processes and antioxidant protection of the erythrocytes in patients with chronic kidney failure on hemodialysis].
    Rud'ko IA, Balashova TS, Pokrovskiĭ IuA, Ermolenko VM, Kubatiev AA.
    Gematol Transfuziol; 1993 Mar; 38(3):24-6. PubMed ID: 8020730
    [Abstract] [Full Text] [Related]

  • 11. [Effects of the treatment with human recombinant erythropoietin on primary hemostasis in uremic patients].
    Cases A, Escolar G, Reverter JC, Garrido M, Ordinas A, López-Pedret J, Castillo R, Revert L.
    Med Clin (Barc); 1990 Nov 17; 95(17):644-7. PubMed ID: 2089202
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Endothelial dysfunction in patients with kidney failure and vascular risk factors: acute effects of hemodialysis.
    Migliacci R, Falcinelli F, Imperiali P, Floridi A, Nenci GG, Gresele P.
    Ital Heart J; 2004 May 17; 5(5):371-7. PubMed ID: 15185901
    [Abstract] [Full Text] [Related]

  • 16. Nucleotide and glutathione status in erythrocytes of children undergoing chronic hemodialysis under erythropoietin treatment.
    Sachs G, Siems W, Grune T, Schmidt G, Gerber G, Zoellner K.
    Biomed Biochim Acta; 1990 May 17; 49(2-3):S123-4. PubMed ID: 2386496
    [Abstract] [Full Text] [Related]

  • 17. Determinants of soluble CD23 antigen levels in hemodialysis patients: effect of 1.25 dihydroxyvitamin D3 and recombinant human erythropoietin treatment.
    Altun B, Erdem Y, Usalan C, Arici M, Haznedaroglu IC, Yasavul U, Turgan C, Caglar S, Kirazli S.
    Clin Nephrol; 1999 Oct 17; 52(4):230-8. PubMed ID: 10543325
    [Abstract] [Full Text] [Related]

  • 18. Soluble P-selectin during a single hemodialysis session in patients with chronic renal failure and erythropoietin treatment.
    Stasko J, Galajda P, Ivanková J, Hollý P, Rozborilová E, Kubisz P.
    Clin Appl Thromb Hemost; 2007 Oct 17; 13(4):410-5. PubMed ID: 17911193
    [Abstract] [Full Text] [Related]

  • 19. [The effect of hemodialysis on levels of beta-endorphin in serum of patients with chronic renal failure treated with erythropoietin].
    Burak W, Grzeszczak W, Trelewicz P, Zukowska-Szczechowska E.
    Przegl Lek; 1996 Oct 17; 53(2):54-7. PubMed ID: 8754321
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.